This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gabriely, I. Articles by Shamoon, H. Search for Related Content PubMed PubMed Citation Articles by Gabriely, I. Articles by Shamoon, H.

Troglitazone Amplifies Counterregulatory Responses to Hypoglycemia in Nondiabetic Subjects¹

Department of Medicine (Division of Endocrinology and Metabolism), Diabetes Research Center, and General Clinical Research Center, Albert Einstein College of Medicine, Bronx, New York 10461

Address all correspondence and requests for reprints to: Ilan Gabriely, M.D., Diabetes Research Center, Albert Einstein College of Medicine, Belfer Building #701, 1300 Morris Park Avenue, Bronx, New York 10461. E-mail: gabriely{at}aecom.yu.edu

As insulin sensitizers, thiazolidinediones could affect the hormonal counterregulatory response to hypoglycemia via the modulatory effect of insulin on counterregulation. In addition, recent studies suggest that thiazolidinediones may influence key steps in glucose sensing and glucoregulatory hormone secretion. We therefore evaluated the effects of a short course of troglitazone on counterregulatory hormones in response to mild hypoglycemia in eight lean nondiabetic subjects. Subjects received either troglitazone (400 mg/day) or placebo for 7 days before stepped hypoglycemia clamp studies (5.0, 4.4, 3.9, and 3.3 mmol/L target plasma glucose steps, 50 min each). The glycemic thresholds for secretion of epinephrine (3.77 ± 0.05 mmol/L) and glucagon (3.83 ± 0.11 mmol/L) were reset to a higher plasma glucose concentration after troglitazone [4.05 ± 0.05 mmol/L (P = 0.003) and 4.10 ± 0.05 mmol/L (P = 0.03), respectively]. In addition, the magnitude of the rise in epinephrine and glucagon concentrations was higher with troglitazone (28% and 11%, respectively; P < 0.05 for both), whereas plasma norepinephrine, GH, and cortisol were comparable in both sets of studies. Endogenous glucose production, measured with [3-³H]glucose, rose by 33% (P < 0.05) in the troglitazone studies compared with 17% (P = NS) after placebo. We conclude that thiazolidinediones may induce an amplification of the counterregulatory response to hypoglycemia characterized by a shift in the glycemic threshold for and an increase in the magnitude of glucagon and epinephrine secretion, and subsequent activation of glucose production.

This article has been cited by other articles:

				I. Gabriely and H. Shamoon Fructose Normalizes Specific Counterregulatory Responses to Hypoglycemia in Patients With Type 1 Diabetes Diabetes, March 1, 2005; 54(3): 609 - 616. [Abstract] [Full Text] [PDF]

				R. Carrillo-Jimenez, G. A. Lamas, and C. H. Hennekens Thiazolidinediones Could Improve Endothelial Dysfunction and Risk of Premature Coronary Heart Disease in HIV-Infected Patients Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2002; 7(4): 207 - 210. [Abstract] [PDF]

				I. Gabriely, M. Hawkins, C. Vilcu, L. Rossetti, and H. Shamoon Fructose Amplifies Counterregulatory Responses to Hypoglycemia in Humans Diabetes, April 1, 2002; 51(4): 893 - 900. [Abstract] [Full Text] [PDF]